肝细胞癌Adv-p53、AAV-HGFK1联合转基因治疗的临床疗效和预后分析  

Clinical efficacy and prognosis of Adv-p53, AAV-HGFK1 combined gene therapy for HCC

作　　者：张法标[1] 方哲平[1] 

机构地区：[1]浙江省台州医院肝胆外科,浙江临海317000

出　　处：《中国现代医生》2015年第26期8-11,F0003,共5页China Modern Doctor

基　　金：浙江省科技计划项目(2009C33096);浙江省台州市科技局资助项目(121ky08)

摘　　要：目的分析肝细胞癌Adv-p53、AAV-HGFK1联合转基因治疗的临床疗效和预后。方法选取我科2009年1月~2012年1月进展期肝癌患者共50例,随机分为重组腺相关病毒-肝细胞生长因子第l螺旋区（recombinant adeno-associated virus-kringle 1 domain of hepatocyte growth factor）AAV-HGFK1＋Adv-p53组和AAV-HGFKI组。比较两组患者治疗后肝穿刺活检标本新生微血管和凋亡细胞率、临床疗效、复发率、生存率。结果 AAV-HGFK1＋Adv-p53组治疗后第14天、第21天的新生微血管数量显著低于AAV-HGFK1组,凋亡细胞率显著高于AAVHGFK1组（P〈0.01）。AAV-HGFK1＋Adv-p53组的疾病控制率为84.00%,显著高于AAV-HGFK1组48.00%（P〈0.05）;两组患者的疾病缓解率差异无统计学意义（P〉0.05）。AAV-HGFK1＋Adv-p53组1年、3年复发率显著低于AAVHGFK1组,1年、3年生存率显著高于AAV-HGFK1组（P〈0.05）。结论 Adv-p53、AAV-HGFK1联合治疗进展期肝细胞癌疗效优于AAV-HGFK1单独治疗,预后更佳。Objective To analyze the clinical efficacy and prognosis of Adv-p53, AAV-HGFK1 combined gene therapy for HCC. Methods Fifty patients with advanced liver cancer in our department from January 2009 to January 2012 were randomly divided into AAV-HGFK1＋Adv-p53 group and AAV-HGFK1 group. The liver biopsy specimens＇ microvessel and apoptosis rate, clinical efficacy and relapse rate were compared in two groups of patients. Results The number of microvessels in AAV-HGFK1 ＋Adv-p53 group 14 days and 21 days was significantly lower than AAV-HGFKI group. The apoptosis rate was significantly higher than that of AAV-HGFK1 group（P〈0.01）. The disease control rate in AAV-HGFK1＋Adv-p53 group was 84.00%, which was significantly higher than 48.00% in the AAV-HGFK1group（P〈0.05）. The remission of the disease in patients had no significant difference between the two groups（P〉0.05）.The 1,3-year recurrence rate in the AAV-HGFK1＋Adv-p53 group was significantly lower than AAV-HGFK1 group,the 1,3-year survival rate was significantly higher than that of AAV-HGFK1 group（ P〈0.05）. Conclusion Adv-p53,AAV-HGFK1 combination therapy for advanced hepatocellular carcinoma is more effective than AAV-HGFK1 alone treatment, while the prognosis is better.

关 键 词：Adv-p53 AAV-HGFK1 转基因治疗 肝细胞癌 预后 

分 类 号：R735.7[医药卫生—肿瘤]